Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer

Completed · Phase 1

Conditions studied: Drug Extravasation, Kidney Cancer

In brief

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. Biomed 101 may protect normal cells from the side effects of interleukin-2. PURPOSE: Phase I trial to study the effectiveness of Biomed 101 in treating patients receiving interleukin-2 for kidney cancer.

Key facts

Study ID

NCT00004890

Run by

BioMedicines

Starts

2000-12-01

Expected to finish

2002-12-01

Last updated by the study team

2013-03-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.